Maria Rosalia Pasca

List of Publications by Year
in descending order

74 papers	4,377 citations	101543 36 h-index	114465 63 g-index
80 all docs	80 docs citations	80 times ranked	4582 citing authors

#	Article	IF	Citations
1	Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis. Science, 2009, 324, 801-804.	12.6	660
2	Global Analysis of the Mycobacterium tuberculosis Zur (FurB) Regulon. Journal of Bacteriology, 2007, 189, 730-740.	2.2	238
3	MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212. Antimicrobial Agents and Chemotherapy, 2012, 56, 324-331.	3.2	190
4	Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5â€“MmpL5 efflux system. Tuberculosis, 2009, 89, 84-90.	1.9	161
5	Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis. Science Translational Medicine, 2012, 4, 150ra121.	12.4	159
6	Benzothiazinones Are Suicide Inhibitors of Mycobacterial Decaprenylphosphoryl-Î²-<scp>d</scp>-ribofuranose 2â€²-Oxidase DprE1. Journal of the American Chemical Society, 2012, 134, 912-915.	13.7	155
7	Rv2686c-Rv2687c-Rv2688c, an ABC Fluoroquinolone Efflux Pump in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2004, 48, 3175-3178.	3.2	148
8	2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1. ACS Chemical Biology, 2015, 10, 705-714.	3.4	116
9	mmpL7 Gene of Mycobacterium tuberculosis Is Responsible for Isoniazid Efflux in Mycobacterium smegmatis. Antimicrobial Agents and Chemotherapy, 2005, 49, 4775-4777.	3.2	110
10	Shifts of Faecal Microbiota During Sporadic Colorectal Carcinogenesis. Scientific Reports, 2018, 8, 10329.	3.3	99
11	4-Aminoquinolone Piperidine Amides: Noncovalent Inhibitors of DprE1 with Long Residence Time and Potent Antimycobacterial Activity. Journal of Medicinal Chemistry, 2014, 57, 5419-5434.	6.4	97
12	The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis. Applied Microbiology and Biotechnology, 2013, 97, 8841-8848.	3.6	92
13	Clinical Isolates of Mycobacterium tuberculosis in Four European Hospitals Are Uniformly Susceptible to Benzothiazinones. Antimicrobial Agents and Chemotherapy, 2010, 54, 1616-1618.	3.2	90
14	Improved BM212 MmpL3 Inhibitor Analogue Shows Efficacy in Acute Murine Model of Tuberculosis Infection. PLoS ONE, 2013, 8, e56980.	2.5	90
15	Decaprenylphosphoryl-β-D-Ribose 2-Epimerase from Mycobacterium tuberculosis is a Magic Drug Target. Current Medicinal Chemistry, 2010, 17, 3099-3108.	2.4	88
16	Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents. European Journal of Medicinal Chemistry, 2011, 46, 5524-5531.	5.5	84
17	Mycobacterium abscessus, an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients. International Journal of Molecular Sciences, 2019, 20, 5868.	4.1	84
18	Efflux pump genes of the resistance-nodulation-division family in Burkholderia cenocepacia genome. BMC Microbiology, 2006, 6, 66.	3.3	82

#	Article	IF	Citations
19	Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents. European Journal of Medicinal Chemistry, 2012, 52, 275-283.	5.5	81
20	Assessment of three Resistance-Nodulation-Cell Division drug efflux transporters of Burkholderia cenocepacia in intrinsic antibiotic resistance. BMC Microbiology, 2009, 9, 200.	3.3	72
21	Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG. Chemistry and Biology, 2015, 22, 917-927.	6.0	72
22	Mechanochemical Synthesis and Biological Evaluation of Novel Isoniazid Derivatives with Potent Antitubercular Activity. Molecules, 2017, 22, 1457.	3.8	71
23	Mycobacterium tuberculosis: drug resistance and future perspectives. Future Microbiology, 2009, 4, 597-614.	2.0	68
24	Deciphering the Role of RND Efflux Transporters in Burkholderia cenocepacia. PLoS ONE, 2011, 6, e18902.	2.5	68
25	Characterization and Heterologous Expression of the Oxalyl Coenzyme A Decarboxylase Gene from Bifidobacterium lactis. Applied and Environmental Microbiology, 2004, 70, 5066-5073.	3.1	65
26	Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance. Molecular Microbiology, 2010, 77, 1172-1185.	2.5	63
27	Differential Roles of RND Efflux Pumps in Antimicrobial Drug Resistance of Sessile and Planktonic Burkholderia cenocepacia Cells. Antimicrobial Agents and Chemotherapy, 2014, 58, 7424-7429.	3.2	45
28	Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3. Applied Sciences (Switzerland), 2020, 10, 623.	2.5	44
29	Trends in discovery of new drugs for tuberculosis therapy. Journal of Antibiotics, 2014, 67, 655-659.	2.0	43
30	Design, synthesis and evaluation of new GEQ derivatives as inhibitors of InhA enzyme and Mycobacterium tuberculosis growth. European Journal of Medicinal Chemistry, 2015, 101, 218-235.	5.5	43
31	In vitro Study of Bedaquiline Resistance in Mycobacterium tuberculosis Multi-Drug Resistant Clinical Isolates. Frontiers in Microbiology, 2020, 11, 559469.	3.5	43
32	Rv2466c Mediates the Activation of TP053 To Kill Replicating and Non-replicating Mycobacterium tuberculosis. ACS Chemical Biology, 2014, 9, 1567-1575.	3.4	41
33	A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK. Scientific Reports, 2018, 8, 3187.	3.3	41
34	Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis. PLoS ONE, 2011, 6, e26675.	2.5	41
35	Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis. European Journal of Medicinal Chemistry, 2013, 70, 37-48.	5.5	39
36	Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis. European Journal of Medicinal Chemistry, 2014, 71, 46-52.	5.5	38

#	Article	IF	Citations
37	Genomic analysis of zinc homeostasis inMycobacterium tuberculosis. FEMS Microbiology Letters, 2008, 287, 1-7.	1.8	37
38	LfrR Is a Repressor That Regulates Expression of the Efflux Pump LfrA in Mycobacterium smegmatis. Antimicrobial Agents and Chemotherapy, 2006, 50, 4044-4052.	3.2	36
39	Phenotypic and Genotypic Characterisation of Burkholderia cenocepacia J2315 Mutants Affected in Homoserine Lactone and Diffusible Signal Factor-Based Quorum Sensing Systems Suggests Interplay between Both Types of Systems. PLoS ONE, 2013, 8, e55112.	2.5	36
40	Synthesis and evaluation of Î±-ketotriazoles and Î±,Î²-diketotriazoles as inhibitors of Mycobacterium tuberculosis. European Journal of Medicinal Chemistry, 2013, 69, 167-173.	5.5	35
41	New prodrugs against tuberculosis. Drug Discovery Today, 2017, 22, 519-525.	6.4	35
42	Iron Acquisition Pathways as Targets for Antitubercular Drugs. Current Medicinal Chemistry, 2016, 23, 4009-4026.	2.4	35
43	A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors. ACS Infectious Diseases, 2017, 3, 428-437.	3.8	34
44	Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis. European Journal of Medicinal Chemistry, 2016, 123, 462-475.	5.5	33
45	Exploring the HME and HAE1 efflux systems in the genus Burkholderia. BMC Evolutionary Biology, 2010, 10, 164.	3.2	32
46	Evaluation of Fluoroquinolone Resistance Mechanisms inPseudomonas aeruginosaMultidrug Resistance Clinical Isolates. Microbial Drug Resistance, 2012, 18, 23-32.	2.0	31
47	New and Old Hot Drug Targets in Tuberculosis. Current Medicinal Chemistry, 2016, 23, 3813-3846.	2.4	26
48	Gut Microbiota Analysis in Postoperative Lynch Syndrome Patients. Frontiers in Microbiology, 2019, 10, 1746.	3.5	23
49	Mycobacterium tuberculosis Phosphoribosylpyrophosphate Synthetase: Biochemical Features of a Crucial Enzyme for Mycobacterial Cell Wall Biosynthesis. PLoS ONE, 2010, 5, e15494.	2.5	19
50	2-Aminooxazole as a Novel Privileged Scaffold in Antitubercular Medicinal Chemistry. ACS Medicinal Chemistry Letters, 2020, 11, 1435-1441.	2.8	18
51	Glutamine amidotransferase activity of NAD+ synthetase from Mycobacterium tuberculosis depends on an amino-terminal nitrilase domain. Research in Microbiology, 2005, 156, 173-177.	2.1	17
52	The Redox State Regulates the Conformation of Rv2466c to Activate the Antitubercular Prodrug TP053. Journal of Biological Chemistry, 2015, 290, 31077-31089.	3.4	17
53	First triclosan-based macrocyclic inhibitors of InhA enzyme. Bioorganic Chemistry, 2020, 95, 103498.	4.1	17
54	Pyrazole and imidazo[1,2-b]pyrazole Derivatives as New Potential Antituberculosis Agents. Medicinal Chemistry, 2019, 15, 17-27.	1.5	17

#	Article	IF	Citations
55	A census of RND superfamily proteins in the Burkholderia genus. Future Microbiology, 2013, 8, 923-937.	2.0	15
56	Gut Microbial Signatures in Sporadic and Hereditary Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 1312.	4.1	14
57	DprE1, a new taxonomic marker in mycobacteria. FEMS Microbiology Letters, 2013, 348, 66-73.	1.8	13
58	A Coumarin-Based Analogue of Thiacetazone as Dual Covalent Inhibitor and Potential Fluorescent Label of HadA in Mycobacterium tuberculosis. ACS Infectious Diseases, 2021, 7, 552-565.	3.8	13
59	Control of MRSA infection and colonisation in an intensive care unit by GeneOhm MRSA assay and culture methods. BMC Infectious Diseases, 2009, 9, 137.	2.9	12
60	Triazolophthalazines: Easily Accessible Compounds with Potent Antitubercular Activity. ChemMedChem, 2016, 11, 1078-1089.	3.2	12
61	The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase. Tuberculosis, 2018, 112, 98-109.	1.9	12
62	New Insights into the Mechanism of Action of the Thienopyrimidine Antitubercular Prodrug TP053. ACS Infectious Diseases, 2020, 6, 313-323.	3.8	11
63	The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme. International Journal of Molecular Sciences, 2022, 23, 771.	4.1	10
64	Nitric oxide-releasing compounds for the treatment of lung infections. Drug Discovery Today, 2021, 26, 542-550.	6.4	9
65	Pyridine-3,4-dicarboximide as starting material for the total synthesis of the natural product eupolauramine and its isomer iso-eupolauramine endowed with anti-tubercular activities. Tetrahedron, 2015, 71, 1555-1559.	1.9	8
66	Design and Synthesis of Pyrano[3,2-b]indolones Showing Antimycobacterial Activity. ACS Infectious Diseases, 2021, 7, 88-100.	3.8	7
67	Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug. Frontiers in Microbiology, 2020, 11, 292.	3.5	5
68	The Antimalarial Mefloquine Shows Activity against Mycobacterium abscessus, Inhibiting Mycolic Acid Metabolism. International Journal of Molecular Sciences, 2021, 22, 8533.	4.1	4
69	Evaluation of the inhibitory activity of (aza)isoindolinoneâ€type compounds: toward in vitro InhA action, Mycobacterium tuberculosis growth and mycolic acid biosynthesis. Chemical Biology and Drug Design, 2016, 88, 740-755.	3.2	1
70	Synthesis and evaluation of Î²-hydroxytriazoles and related compounds as antitubercular agents. French-Ukrainian Journal of Chemistry, 2015, 3, 82-96.	0.4	1
71	Fighting Against Resistant Strains: The Case of Benzothiazinones and Dinitrobenzamides. , 0, , .		1
72	The Clitocybins and 2-Substituted-Isoindolin-1-Ones: Synthesis and in Vitro Antimycobacterial Activities. Journal of Advances in Chemistry, 0, 16, 5387-5394.	0.1	1

#	Article	IF	Citations
73	TOWARDS NEW ANTITUBERCULAR DRUGS. Istituto Lombardo - Accademia Di Scienze E Lettere - Rendiconti Di Scienze, 2015, , .	0.0	0
74	Editorial: New Approaches Against Drug-Resistant M. tuberculosis. Frontiers in Microbiology, 2021, 12, 681420.	3.5	0